April 2010 Editor's Picks: Products from Camfil Farr and K-Tron - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

April 2010 Editor's Picks: Products from Camfil Farr and K-Tron

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

product Camfil Farr Air Pollution Control
Dust collector extends filters’ service lives

The Gold Series High Vacuum (GSHV) dust collector from Camfil Farr Air Pollution Control (Jonesboro, AR) controls emissions in applications performed under pressures as high as 17 in. Hg vacuum or 8 psi. The unit is housed in a reinforced dust-capture vessel designed for use as a central vacuum system, positive or negative product receiver, or high-pressure bin vent. The GSHV collector can be provided with two or four Gold Cone HemiPleat filter cartridges, which are available in efficiencies of 99.99% and 99.999% on 0.5-µm particles.

The machine’s cyclonic tangential inlet removes most of the dust as it enters the collector, thus minimizing filters’ contact with the dust and extending their service lives. The device also includes a pulse-cleaning system that operators regulate through a user-friendly, solid-state control panel. The dust collector is available with a horizontal explosion vent for combustible-dust applications and a bag-in–bag-out access door and continuous liner discharge for pharmaceutical dusts.


productK-Tron
Material flow aid prevents bridging and rat-holing

K-Tron (Pitman, NJ) offers its ActiFlow bulk-solids activator, a nonproduct contact device that comprises a vibratory drive and an intelligent control unit. The device operates with the K-Tron Control Module (KCM) to activate the material inside the hopper continuously. The KCM unit’s self-tuning algorithm monitors the system and continuously adjusts the ActiFlow’s frequency and amplitude, according to changing material-flow conditions, to maintain flow within the hopper. The activator and KCM thus prevent the formation of bridges and ratholes.

The ActiFlow machine is designed to eliminate the need for mechanical agitators with secondary motors and gearboxes and to eliminate the need for flexible side-wall agitation devices or aeration pads. The ActiFlow device is bolted to the outside of the extension hopper’s rear wall above the feeder, thus reducing headroom requirements. ActiFlow is designed to simplify the cleaning process during material changeover and is suitable for pharmaceutical applications.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here